Post by
stocksaregood on Apr 23, 2021 8:22am
Nice write up from TD
TD Investment Conclusion We have increased our target price to C$10.50 (from C$10.00) due to the acquisition of CRH Medical as well as a modest improvement in peer-group valuations. We believe that the recent share-price weakness has created an attractive buying opportunity, particularly given that it has just closed the highly accretive and strategic acquisition of CRH that positions it well to continue its active M&A strategy and pursue a potential U.S. IPO later this year.
Comment by
straightup on Apr 23, 2021 3:59pm
Nice!!! Thanks for sharing!